Patents Assigned to JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG
-
Patent number: 10253294Abstract: The present invention relates to a method for producing dendritic cells with increased capability to activate T cells, to dendritic cells obtainable by such a method, and to a pharmaceutical composition comprising such dendritic cells.Type: GrantFiled: December 18, 2014Date of Patent: April 9, 2019Assignee: JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURGInventors: Marion Heuer, Manfred Lutz, Andreas Beilhack
-
Patent number: 10234525Abstract: In a method and apparatus for acquiring magnetic resonance (MR) data from a predetermined volume within an examination object, a control protocol for a gradient echo sequence is selected that specifies that gradient moments produced in said gradient echo sequence be balanced along all three spatial directions. In this gradient echo sequence a slice selection gradient is activated in a slice selection direction that produces a balanced gradient moment, with simultaneous radiation of an RF pulse that simultaneously excites nuclear spins in multiple slices of the examination object, with said excitation being repeated according to a repetition time. A phase of MR signals to be acquired from a same one of said multiple layers is varied from repetition time-to-repetition time.Type: GrantFiled: December 2, 2016Date of Patent: March 19, 2019Assignees: Julius-Maximilians-Universitaet-Wuerzburg, Siemens Healthcare GmbHInventors: Peter Speier, Daniel Staeb
-
Patent number: 10105414Abstract: The present invention relates to a pharmaceutical composition comprising a (poly)peptide which comprises or consists of QEP or a QEP derivative thereof a nucleic acid molecule encoding said (poly)peptide or a vector comprising said nucleic acid molecule, for use in the prevention or in the treatment of a disease or disorder caused by, physiologically linked to or associated with glucose and/or galactose uptake, wherein said pharmaceutical composition is to be administered under a high-sugar condition. Furthermore, the pharmaceutical composition of the invention is for use in increasing insulin sensitivity. The invention further relates to a food composition comprising said (poly)peptide. The invention further relates to a method of screening for and/or identifying a compound suitable to prevent or treat said disease or disorder under a high-sugar condition.Type: GrantFiled: April 23, 2015Date of Patent: October 23, 2018Assignee: Julius-Maximilians-Universität WürzburgInventors: Alexandra Friedrich, Jürgen Groll, Hermann Koepsell, Maike Veyhl-Wichmann
-
Publication number: 20180271086Abstract: The present invention relates to a gas delivery device comprising a gas releasing molecule and a gas permeable membrane. The invention also relates to the use of the gas delivery device for delivery of gas to an extracorporeal transplant, extracorporeal cells, a brain-dead transplant donor or foodstuff and in therapy. The invention further relates to the use of a gas permeable and liquid and solid impermeable membrane to separate a gas releasing molecule and its non-gaseous degradation products from an extracorporeal transplant, extracorporeal cells, a brain-dead transplant donor or foodstuff.Type: ApplicationFiled: January 7, 2016Publication date: September 27, 2018Applicant: Julius-Maximilians-Universitaet WuerzburgInventors: Lorenz MEINEL, Christoph STEIGER, Christian WUNDER
-
Patent number: 9957329Abstract: This application relates to neurological inflammatory diseases, such as multiple sclerosis, and to methods of administering a Factor XII inhibitor to prevent, treat, or otherwise ameliorate the effects of a neurological inflammatory disease, such as multiple sclerosis. Agents and pharmaceutical compositions comprising agents which inhibit the activity of FXII are also provided.Type: GrantFiled: January 31, 2013Date of Patent: May 1, 2018Assignees: CSL Behring GmbH, CSL Ltd., Julius-Maximilians-Universitaet-Wuerzburg, Westfaelische Wilhelms-Universitaet MuensterInventors: Sven Meuth, Kerstin Goebel, Christoph Kleinschnitz, Brent McKenzie, Marc Nolte
-
Publication number: 20180080943Abstract: The present invention relates to the biomarkers for predicting the clinical response to anti-LPS immunoglobulin treatments in patients in need thereof. In particular, the invention provides methods for predicting the clinical response to an anti-LPS immunoglobulin treatment in a patient in need thereof, said method comprising the steps of evaluating the expression of a predictive biomarker selected from the group consisting of CD14, CD68, TLR4, TLR7, IL6, IL8, IL10, IFN-alpha, IGF1, CXCL1, CXCL9, CXCL10, RAGE, GDNF, BCHE, and combination thereof, in said patient.Type: ApplicationFiled: April 14, 2016Publication date: March 22, 2018Applicants: JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG, IGNOVA GMBHInventors: Günter SPROTTE, Ana Maria WAAGA-GASSER
-
Patent number: 9869674Abstract: The invention relates to a method for determining the presence of an analyte by means of a distribution of small magnetic particles. According to said method, the magnetizations of the small particles are oriented in relation to each other by means of an outer magnetic focusing field; once the focussing field has been terminated, the magnetizations of the small particles are rotated asynchronously to the magnetic field by means of an outer magnetic field of suitable field intensity and rotational frequency, which rotates about a longitudinal axis (z); the temporal course of the superpositioned transverse magnetization of the set of particles is detected; and the presence of the analyte is deduced from the detected temporal course. The invention also relates to a corresponding device (1).Type: GrantFiled: April 1, 2011Date of Patent: January 16, 2018Assignees: Hochschule für angewandte Wissenschaften Fachhochschule Würzburg-Schweinfurt, Julius-Maximilians-Universität-WürzburgInventors: Martin Rueckert, Volker C. Behr, Thomas Kampf
-
Patent number: 9814789Abstract: A radiopharmaceutical composition is disclosed comprising novel iodometomidate derivatives of formula (I) which bind specifically to adrenal enzymes and which exhibit an improved stability. The compounds of formula (I) are suitable for use in a diagnostic imaging method, e.g. for diagnosis of adrenocortical carcinoma. The compounds of formula (I) are further suitable for use in the treatment of adrenocortical carcinoma, by means of radionuclide therapy.Type: GrantFiled: September 26, 2013Date of Patent: November 14, 2017Assignee: Julius-Maximilians-Universität WürzburgInventors: Bruno Allolio, Andreas Schirbel, Stefanie Hahner
-
Publication number: 20170152229Abstract: The present invention relates to tetrahydroisoquinolinone derivatives, a pharmaceutical composition comprising the same and the use of these derivatives in the inhibition of the Hsp70 protein. The compounds are useful in the treatment or inhibition of cancer, autoimmune disease, rheumatoid arthritis, inflammatory bowel disease and psoriasis.Type: ApplicationFiled: June 3, 2014Publication date: June 1, 2017Applicant: Julius-Maximilians-Universitaet WuerzburgInventors: Manik CHATTERJEE, Andreas HARTUNG, Ulrike HOLZGRABE, Elisabeth MUELLER, Ulrich PEINZ, Christoph SOTRIFFER, David ZILIAN
-
Patent number: 9649816Abstract: The present invention relates to a process for the production of a multi-layered material having anisotropic pores. It further relates to a multi-layered material which can be produced by the process according to the invention, and to the use of a multi-layered material as a chondral support matrix, a meniscus support matrix or an intervertebral disc support matrix.Type: GrantFiled: December 10, 2012Date of Patent: May 16, 2017Assignee: JULIUS-MAXIMILIANS-UNIVERSITAET WUERZBURGInventors: Kai Stuckensen, Uwe Gbureck, Juergen Groll
-
Patent number: 9526803Abstract: Described herein is a diagnostic chewing gum for identifying the presence of pathogens detectable via the mouth, in particular pathogens residing in nasal, oropharyngeal, laryngeal, oesophageal, ocular and/or pulmonal tissue of a user, more particularly pathogens selected from among a virus, bacterium, protozoa, prion, fungus or a combination thereof. The inventive diagnostic chewing gum includes a base material or particles (3) embedded and/or attached to the base material and an element (1, 5-7), like e.g. a releasable flavor molecule, attached to the base material and/or the particles, for the generation of a change in the chewing gum directly detectable by the user, wherein the element (1, 5-7) generates the change upon direct or indirect contact with a marker (4) which is released by the pathogens, or, in case of a virus or prion, by the cellular structure hosting it.Type: GrantFiled: March 8, 2013Date of Patent: December 27, 2016Assignee: Julius-Maximilians-Universitaet WuerzburgInventors: Lorenz Meinel, Matthias Schnabelrauch, Falko Schlottig
-
Patent number: 9422365Abstract: The invention concerns a peptide or arrangement of peptides forming a Staphylococcus aureus epitope binding site comprising a first amino acid sequence and a second amino acid sequence, wherein the first amino acid sequence is at least 88% identical to sequence SEQ ID NO:1 and wherein the second amino acid sequence is at least 88% identical to sequence SEQ ID NO: 2.Type: GrantFiled: September 21, 2012Date of Patent: August 23, 2016Assignee: JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURGInventors: Knut Ohlsen, Udo Lorenz, Roland E. Kontermann
-
Patent number: 9383363Abstract: The invention relates to the use of LASP-1 in a urine sample obtained from a subject for diagnosing and/or grading transitional cell carcinoma. The invention furthermore relates to a method for diagnosing transitional cell carcinoma comprising detecting the presence or absence of LASP-1 in a urine sample obtained from a subject, wherein the presence of LASP-1 above 1 ng/500 ?l urine is indicative for transitional cell carcinoma and a method for grading transitional cell carcinoma comprising determining the level of LASP-1 in a urine sample obtained from a subject, wherein the level of LASP-1 correlates with the grade of the transitional cell carcinoma.Type: GrantFiled: December 6, 2012Date of Patent: July 5, 2016Assignee: Julius-Maximilians-Universität-WürzburgInventor: Elke Butt
-
Publication number: 20160109449Abstract: The invention concerns antibodies or fragments thereof that are directed against a Staphylococcus aureus epitope.Type: ApplicationFiled: December 30, 2015Publication date: April 21, 2016Applicant: JULIUS-MAXIMILIANS-UNIVERSITAET WUERZBURGInventors: Knut Ohlsen, Udo Lorenz
-
Patent number: 9260511Abstract: The invention concerns antibodies or fragments thereof that are directed against a Staphylococcus aureus epitope.Type: GrantFiled: November 12, 2013Date of Patent: February 16, 2016Assignee: JULIUS-MAXIMILIANS-UNIVERSITAET WUERZBURGInventors: Knut Ohlsen, Udo Lorenz
-
Publication number: 20150023879Abstract: The document proposes a diagnostic chewing gum for identifying the presence of pathogens detectable via the mouth, in particular residing in nasal, oropharyngeal, laryngeal, oesophageal, ocular and/or pulmonal tissue of a user, comprising a base material or particles (3) embedded and/or attached to said base material; an element (1, 5-7), like e.g. a releasable flavor molecule, attached to said base material and/or said particles, for the generation of a change in the chewing gum directly detectable by the user; wherein said pathogen is selected from the group consisting of virus, bacterium, protozoa, prion, fungus or a combination thereof; and wherein the element (1, 5-7) generates the change upon direct or indirect contact with a marker (4) which is released by said pathogens, or, in case of a virus or prion, by the cellular structure hosting it.Type: ApplicationFiled: March 8, 2013Publication date: January 22, 2015Applicant: Julius-Maximilians-Universitaet WuerzburgInventors: Lorenz Meinel, Matthias Schnabelrauch, Falko Schlottig
-
Publication number: 20140370530Abstract: The invention relates to the use of LASP-1 in a urine sample obtained from a subject for diagnosing and/or grading transitional cell carcinoma. The invention furthermore relates to a method for diagnosing transitional cell carcinoma comprising detecting the presence or absence of LASP-1 in a urine sample obtained from a subject, wherein the presence of LASP-1 above 1 ng/500 ?l urine is indicative for transitional cell carcinoma and a method for grading transitional cell carcinoma comprising determining the level of LASP-1 in a urine sample obtained from a subject, wherein the level of LASP-1 correlates with the grade of the transitional cell carcinoma.Type: ApplicationFiled: December 6, 2012Publication date: December 18, 2014Applicant: JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURGInventor: Elke Butt
-
Patent number: 8889425Abstract: Described is a chimeric peptide, comprising, in order, (a) a first detectable label (b) a cAMP binding moiety having only one cAMP binding site and (c) a second detectable label least two detectable labels is describe. The chimeric peptide is useful for direct determination of cAMP concentration in vitro and/or in vivo. Also described are nucleic acids encoding the chimeric peptide, methods of making and modifying the chimeric peptide, a method for determining the cAMP concentration, and kits.Type: GrantFiled: November 26, 2004Date of Patent: November 18, 2014Assignee: Bayerische Julius-Maximilians-Universität WürzburgInventors: Viacheslav Nikolaev, Moritz Bünemann, Martin J. Lohse
-
Patent number: 8877718Abstract: The present invention relates to naphthoquinone derivatives isolated from solid callus cultures from two species of the palaeotropical plant families Dioncophyllaceae and Ancistrocladaceae. It further relates to methods of their production as well as to their use as antiinfective and antitumoral pharmaceuticals.Type: GrantFiled: February 6, 2009Date of Patent: November 4, 2014Assignee: Julius-Maximilians-Universität WürzburgInventors: Gerhard Bringmann, Stefan Rüdenauer, Reto Brun, Andreas Irmer, Ralf Bargou, Manik Chatterjee, Anastasia Voskobojnik
-
Patent number: 8796428Abstract: The invention relates to an antibody specific to Erk1/2 phosphorylated at Thr188 and a method for producing the same. The invention also relates to an in vitro method for determining the presence of phosphorylated Erk1/2 in a sample using the antibody of the invention. Therefore, the invention also comprises an assay for diagnosing a heart disease in vitro comprising the antibody of the invention and certain uses of the antibody. Moreover the invention relates to a peptide used to produce the antibody.Type: GrantFiled: November 26, 2009Date of Patent: August 5, 2014Assignee: Julius-Maximilians-Universitaet WuerzburgInventors: Martin J. Lohse, Kristina Lorenz